B-cell small lymphocytic lymphoma refractory – European Clinical Trials Information Network

Study of NX-5948 in adults with relapsed or resistant chronic lymphocytic leukemia and small lymphocytic lymphoma who previously received BTK inhibitor and BCL-2 inhibitor treatment

Thu, 30 Apr 2026 13:08:01 +0000

This study focuses on patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) that has returned or not responded to previous treatments. These are types of blood cancers that affect certain white blood cells. The study will test a new medication called NX-5948, which is taken as a capsule by mouth, in patients who have already been treated with two specific types of cancer medicines: a Bruton’s Tyrosine Kinase inhibitor and a B-cell Lymphoma-2 inhibitor.

The purpose of this research is to determine how well NX-5948 works in treating adults with CLL or SLL that has come back or not responded to previous treatments. During the study, participants will receive NX-5948 capsules daily. The maximum daily dose that may be given is 600 milligrams, and treatment may continue for up to 28 days per treatment cycle.

Throughout the study, doctors will monitor participants’ health through regular check-ups and various medical tests. They will look at how the cancer responds to the treatment and keep track of any side effects that may occur. The study will collect information about how long the treatment effects last and how it affects participants’ overall health.

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Thu, 30 Apr 2026 13:07:59 +0000

This clinical trial studies treatments for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in patients whose disease has returned or did not respond to previous treatments. The study compares two treatment combinations: sonrotoclax plus either obinutuzumab or rituximab versus venetoclax plus rituximab. These medications work by targeting and destroying cancer cells in different ways.

The study aims to determine which treatment combination is more effective at preventing the disease from getting worse. Patients will receive either tablets of sonrotoclax or venetoclax to take by mouth, along with infusions of obinutuzumab or rituximab given through a vein. The medications will be given over several months according to a specific schedule.

Throughout the study, doctors will monitor how well the treatments work by performing various tests and examining patients regularly. They will check for the presence of cancer cells in the blood, measure how long patients live without their disease getting worse, and track any side effects that may occur. The study is expected to continue until the end of 2031.